Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Ups Guidance While Pharma Head Highlights NHL Drug Copanlisib

Executive Summary

Bayer has initiated the regulatory filing process in the US for its pipeline non-Hodgkin's lymphoma drug copanlisib, head of pharma Dieter Weinand said during the company's first quarter earnings call during which the German group also said it was upping guidance for the year.

You may also be interested in...



Keeping Track Of New Drugs: US FDA Review Queue Adds Spark Gene Therapy, Amgen Migraine Antibody, Bayer Oncologic

The latest news about novel agent applications from our FDA Performance Tracker.

Execs On The Move, July 2020

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Listening Well And Early To The Signs Of Alzheimer’s Disease

The stereotypical view of an Alzheimer’s patient as an elderly person needs to change and interventions made earlier in the disease course, while we wait for novel drug therapies, said experts at a recent virtual meeting.

Topics

Related Companies

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel